Anti-Thyroid Drugs Market Report 2026

The anti-thyroid drugs market size has grown marginally in recent years. It will grow from $2.49 billion in 2025 to $2.54 billion in 2026 at a compound annual growth rate (CAGR) of 2%. The growth in the historic period can be attributed to high prevalence of hyperthyroidism, availability of oral therapies, widespread diagnostic testing, established endocrine care, use in radiation protection.

The anti-thyroid drugs market size is expected to see steady growth in the next few years. It will grow to $2.85 billion in 2030 at a compound annual growth rate (CAGR) of 2.9%. The growth in the forecast period can be attributed to growth in autoimmune thyroid diseases, improved screening programs, rising healthcare access, innovation in thyroid regulation therapies, aging population. Major trends in the forecast period include rising diagnosis of thyroid disorders, growing use of thionamide-based drugs, expansion of outpatient thyroid management, increased monitoring of hormone levels, improved drug safety profiles.

The rising prevalence of thyroid cancer is anticipated to drive the growth of the anti-thyroid drugs market in the coming years. Thyroid cancer is a condition affecting the thyroid gland, located near the base of the throat, which produces hormones that regulate body temperature, heart rate, blood pressure, and weight. The increasing occurrence of thyroid cancer is mainly attributed to higher exposure to medical radiation and environmental carcinogens. Anti-thyroid drugs assist in the early detection of thyroid cancer, which can lead to improved treatment outcomes. For example, in August 2023, the American Society of Clinical Oncology, a US-based community of oncologists and surgeons, reported that in the United States, approximately 43,720 adults (12,540 men and 31,180 women) were diagnosed with thyroid cancer in 2023, with an estimated 2,120 deaths (970 men and 1,150 women) expected in the same year. Consequently, the increasing prevalence of thyroid cancer is driving the growth of the anti-thyroid drugs market.

Major companies operating in the anti-thyroid drugs market are concentrating on developing innovative products, such as monoclonal antibodies, to enhance patient outcomes, minimize adverse effects, and reinforce their competitive edge. Monoclonal antibodies are laboratory-engineered proteins designed to specifically target certain molecules in the body, enabling more effective disease treatment. For example, in March 2025, Innovent Biologics, Inc., a biotechnology company based in China, announced that SYCUME, an anti-IGF-1R monoclonal antibody, received approval from China's National Medical Products Administration (NMPA) for treating thyroid eye disease (TED). SYCUME is the first therapy of its kind approved in China and the second globally, providing a novel, effective treatment that substantially reduces proptosis and inflammation while enhancing patients’ quality of life. The approval was based on favorable clinical trial outcomes showing SYCUME’s capacity to meet the unmet needs of TED patients, offering a safer and more accessible alternative to current treatments.

In October 2023, Amgen Inc., a US-based biotechnology company, completed the acquisition of Horizon Therapeutics plc for approximately $27.8 billion. Through this acquisition, Amgen intends to strengthen its anti-thyroid drug portfolio by incorporating Horizon Therapeutics’ innovative therapies for thyroid disorders, facilitating the development of advanced treatments for patients with hyperthyroidism and other thyroid-related conditions. Horizon Therapeutics plc is an Ireland-based biopharmaceutical company focused on rare and specialty diseases, with a strong history in developing anti-thyroid drugs and therapies for endocrine disorders.

Major companies operating in the anti-thyroid drugs market are Mylan N.V., Abbott Laboratories, GlaxoSmithKline plc, Merck & Co., Pfizer Inc., Allergan plc, RLC LABS Inc., Lannett Company Inc., Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., Aspen Pharmacare Holdings Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Lupin Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Ltd., Alkem Laboratories Ltd., Akorn Inc.

North America was the largest region in the anti-thyroid drugs market in 2025. The Middle East is expected to be the fastest-growing region in the anti-thyroid drugs market during the forecast period. The regions covered in the anti-thyroid drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-thyroid drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of imported iodine based compounds and synthetic drug ingredients used in pharmaceutical manufacturing. These impacts are most pronounced in Asia Pacific markets that rely on cross border sourcing for specialty chemical inputs. Rising tariff related expenses have placed pressure on production costs and drug pricing across multiple therapeutic categories. This has influenced procurement decisions and inventory planning for manufacturers and distributors. However, tariffs are also supporting regional pharmaceutical production, local raw material sourcing, and stronger supply chain resilience over the long term.

The anti-thyroid drugs market research report is one of a series of new reports that provides anti-thyroid drugs market statistics, including anti-thyroid drugs industry global market size, regional shares, competitors with a anti-thyroid drugs market share, detailed anti-thyroid drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-thyroid drugs industry. This anti-thyroid drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-thyroid drugs are agents that work by inhibiting the production of thyroid hormones or by decreasing their activity. Moreover, they are recommended for use in radioactive iodine uptake tests to evaluate thyroid function and protect the thyroid gland in the event of radiation exposure.

The primary categories of anti-thyroid medications include thionamides, which inhibit hormone synthesis, and iodides, which suppress hormone release. Ethionamide drugs work pharmacologically to restore normal thyroid hormone levels. These medications are available for oral and intravenous administration and are supplied through wholesalers and distributors, retail chains, online platforms, and other channels.

The anti-thyroid drugs market consists of sales of levothyroxine, propylthiouracil, and methimazole. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.